25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Eli Lilly and Company
Buy, Hold or Sell?

Let's analyze Lilly together

I guess you are interested in Eli Lilly and Company. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Eli Lilly and Company. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Eli Lilly and Company

I send you an email if I find something interesting about Eli Lilly and Company.

1. Quick Overview

1.1. Quick analysis of Lilly (30 sec.)










1.2. What can you expect buying and holding a share of Lilly? (30 sec.)

How much money do you get?

How much money do you get?
R$0.04
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
R$0.50
Expected worth in 1 year
R$0.60
How sure are you?
83.9%

+ What do you gain per year?

Total Gains per Share
R$0.33
Return On Investment
0.2%

For what price can you sell your share?

Current Price per Share
R$147.00
Expected price per share
R$135.19 - R$176.32
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Lilly (5 min.)




Live pricePrice per Share (EOD)
R$147.00
Intrinsic Value Per Share
R$-1.61 - R$-1.97
Total Value Per Share
R$-1.11 - R$-1.47

2.2. Growth of Lilly (5 min.)




Is Lilly growing?

Current yearPrevious yearGrowGrow %
How rich?$2.3b$1.8b$241.1m11.4%

How much money is Lilly making?

Current yearPrevious yearGrowGrow %
Making money$1.8b$1.6b$211.1m11.5%
Net Profit Margin18.7%22.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Lilly (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Lilly?

Welcome investor! Lilly's management wants to use your money to grow the business. In return you get a share of Lilly.

First you should know what it really means to hold a share of Lilly. And how you can make/lose money.

Speculation

The Price per Share of Lilly is R$147.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lilly.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lilly, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is R$0.50. Based on the TTM, the Book Value Change Per Share is R$0.02 per quarter. Based on the YOY, the Book Value Change Per Share is R$0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is R$0.06 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lilly.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 R$% of Price per ShareR$% of Price per ShareR$% of Price per ShareR$% of Price per ShareR$% of Price per Share
Usd Eps0.110.1%0.070.0%0.060.0%0.060.0%0.050.0%
Usd Book Value Change Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Dividend Per Share0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Price Per Share29.39-21.00-46.63-66.66-51.51-
Price to Earnings Ratio66.90--413.02-211.86-223.12-157.43-
Price-to-Total Gains Ratio2,389.80-2,016.15-3,611.14-17,950.69-12,574.57-
Price to Book Ratio334.84-264.32-702.97-1,581.74-1,191.78-
Price-to-Total Gains Ratio2,389.80-2,016.15-3,611.14-17,950.69-12,574.57-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share25.5633
Number of shares39
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.010.01
Gains per Quarter (39 shares)0.560.42
Gains per Year (39 shares)2.261.69
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
121-811-8
231-621-6
352-432-4
463-252-2
5830630
61042732
71154844
81356946
914681058
101661012510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%27.04.00.087.1%27.04.00.087.1%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%22.09.00.071.0%22.09.00.071.0%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%31.00.00.0100.0%31.00.00.0100.0%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%26.05.00.083.9%26.05.00.083.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Eli Lilly and Company compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0270.024+15%0.022+23%0.020+37%0.016+68%
Book Value Per Share--0.5050.450+12%0.399+27%0.304+66%0.346+46%
Current Ratio--1.1141.1140%1.152-3%1.197-7%1.269-12%
Debt To Asset Ratio--0.8100.8110%0.790+3%0.841-4%0.800+1%
Debt To Equity Ratio--4.2944.343-1%3.764+14%6.195-31%5.534-22%
Dividend Per Share--0.0430.059-27%0.035+23%0.043+2%0.035+24%
Eps--0.6320.391+62%0.346+83%0.332+90%0.279+127%
Free Cash Flow Per Share--0.002-0.034+1531%0.030-92%0.024-90%0.024-90%
Free Cash Flow To Equity Per Share--0.0600.010+482%0.002+3389%-0.001+101%-0.001+101%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1.970--------
Intrinsic Value_10Y_min---1.615--------
Intrinsic Value_1Y_max--0.019--------
Intrinsic Value_1Y_min--0.019--------
Intrinsic Value_3Y_max---0.107--------
Intrinsic Value_3Y_min---0.099--------
Intrinsic Value_5Y_max---0.433--------
Intrinsic Value_5Y_min---0.388--------
Market Cap3970881675264.000-15%4565703542538.2403262065789829.120+40%7242807137280.000-37%10354303577055.232-56%8001818905730.809-43%
Net Profit Margin--0.2630.187+41%0.220+19%0.214+23%0.193+36%
Operating Margin----0%0.281-100%0.246-100%0.236-100%
Operating Ratio--0.8010.832-4%0.956-16%0.935-14%0.914-12%
Pb Ratio291.216-15%334.839264.320+27%702.970-52%1581.737-79%1191.778-72%
Pe Ratio58.181-15%66.896-413.024+717%211.857-68%223.121-70%157.433-58%
Price Per Share147.000-15%169.020120.760+40%268.125-37%383.311-56%296.223-43%
Price To Free Cash Flow Ratio15658.051-15%18003.5636990.638+158%549.006+3179%4309.310+318%2780.200+548%
Price To Total Gains Ratio2078.452-15%2389.7952016.148+19%3611.140-34%17950.688-87%12574.571-81%
Quick Ratio--0.4120.417-1%0.687-40%0.602-32%0.573-28%
Return On Assets--0.2370.158+51%0.183+30%0.180+32%0.160+48%
Return On Equity--1.2580.851+48%0.871+44%1.337-6%1.320-5%
Total Gains Per Share--0.0710.083-15%0.057+23%0.062+13%0.051+38%
Usd Book Value--2371213450.0002113624075.000+12%1872463902.500+27%1428421556.000+66%1626548967.419+46%
Usd Book Value Change Per Share--0.0050.004+15%0.004+23%0.003+37%0.003+68%
Usd Book Value Per Share--0.0880.078+12%0.069+27%0.053+66%0.060+46%
Usd Dividend Per Share--0.0080.010-27%0.006+23%0.007+2%0.006+24%
Usd Eps--0.1100.068+62%0.060+83%0.058+90%0.048+127%
Usd Free Cash Flow--11025260.000-157731647.500+1531%139615615.000-92%99583835.000-89%64247635.484-83%
Usd Free Cash Flow Per Share--0.000-0.006+1531%0.005-92%0.004-90%0.004-90%
Usd Free Cash Flow To Equity Per Share--0.0100.002+482%0.000+3389%0.000+101%0.000+101%
Usd Market Cap690536323328.410-15%793975846047.400567273240851.284+40%1259524161172.992-37%1800613392049.905-56%1391516307706.588-43%
Usd Price Per Share25.563-15%29.39321.000+40%46.627-37%66.658-56%51.513-43%
Usd Profit--2967190244.0401835667695.466+62%1624479154.925+83%1561105091.641+90%1309393630.356+127%
Usd Revenue--11303524735.5369731323932.484+16%7379348133.465+53%7359726875.431+54%6810162446.070+66%
Usd Total Gains Per Share--0.0120.014-15%0.010+23%0.011+13%0.009+38%
 EOD+4 -4MRQTTM+24 -10YOY+22 -135Y+23 -1210Y+22 -13

3.3 Fundamental Score

Let's check the fundamental score of Eli Lilly and Company based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1558.181
Price to Book Ratio (EOD)Between0-1291.216
Net Profit Margin (MRQ)Greater than00.263
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.412
Current Ratio (MRQ)Greater than11.114
Debt to Asset Ratio (MRQ)Less than10.810
Debt to Equity Ratio (MRQ)Less than14.294
Return on Equity (MRQ)Greater than0.151.258
Return on Assets (MRQ)Greater than0.050.237
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Eli Lilly and Company based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.894
Ma 20Greater thanMa 50167.658
Ma 50Greater thanMa 100168.322
Ma 100Greater thanMa 200166.605
OpenGreater thanClose157.000
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Fundamental data was last updated by Penke on 2024-10-23 18:50:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Lilly earns for each R$1 of revenue.

  • Above 10% is considered healthy but always compare Lilly to the Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 26.3% means that R$0.26 for each R$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eli Lilly and Company:

  • The MRQ is 26.3%. The company is making a huge profit. +2
  • The TTM is 18.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ26.3%TTM18.7%+7.6%
TTM18.7%YOY22.0%-3.3%
TTM18.7%5Y21.4%-2.7%
5Y21.4%10Y19.3%+2.0%
4.3.1.2. Return on Assets

Shows how efficient Lilly is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lilly to the Drug Manufacturers - General industry mean.
  • 23.7% Return on Assets means that Lilly generated R$0.24 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eli Lilly and Company:

  • The MRQ is 23.7%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 15.8%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ23.7%TTM15.8%+8.0%
TTM15.8%YOY18.3%-2.5%
TTM15.8%5Y18.0%-2.3%
5Y18.0%10Y16.0%+2.0%
4.3.1.3. Return on Equity

Shows how efficient Lilly is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lilly to the Drug Manufacturers - General industry mean.
  • 125.8% Return on Equity means Lilly generated R$1.26 for each R$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eli Lilly and Company:

  • The MRQ is 125.8%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 85.1%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ125.8%TTM85.1%+40.7%
TTM85.1%YOY87.1%-2.0%
TTM85.1%5Y133.7%-48.6%
5Y133.7%10Y132.0%+1.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Eli Lilly and Company.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Lilly is operating .

  • Measures how much profit Lilly makes for each R$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lilly to the Drug Manufacturers - General industry mean.
  • An Operating Margin of 0.0% means the company generated R$0.00  for each R$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eli Lilly and Company:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY28.1%-28.1%
TTM-5Y24.6%-24.6%
5Y24.6%10Y23.6%+1.0%
4.3.2.2. Operating Ratio

Measures how efficient Lilly is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.80 means that the operating costs are R$0.80 for each R$1 in net sales.

Let's take a look of the Operating Ratio trends of Eli Lilly and Company:

  • The MRQ is 0.801. The company is less efficient in keeping operating costs low.
  • The TTM is 0.832. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.801TTM0.832-0.031
TTM0.832YOY0.956-0.124
TTM0.8325Y0.935-0.103
5Y0.93510Y0.914+0.021
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Eli Lilly and Company.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Lilly is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A Current Ratio of 1.11 means the company has R$1.11 in assets for each R$1 in short-term debts.

Let's take a look of the Current Ratio trends of Eli Lilly and Company:

  • The MRQ is 1.114. The company is just able to pay all its short-term debts.
  • The TTM is 1.114. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.114TTM1.1140.000
TTM1.114YOY1.152-0.038
TTM1.1145Y1.197-0.082
5Y1.19710Y1.269-0.073
4.4.3.2. Quick Ratio

Measures if Lilly is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lilly to the Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.41 means the company can pay off R$0.41 for each R$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eli Lilly and Company:

  • The MRQ is 0.412. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.417. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.412TTM0.417-0.006
TTM0.417YOY0.687-0.270
TTM0.4175Y0.602-0.185
5Y0.60210Y0.573+0.030
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Eli Lilly and Company.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Lilly assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lilly to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.81 means that Lilly assets are financed with 81.0% credit (debt) and the remaining percentage (100% - 81.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Eli Lilly and Company:

  • The MRQ is 0.810. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.811. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.810TTM0.811-0.001
TTM0.811YOY0.790+0.022
TTM0.8115Y0.841-0.029
5Y0.84110Y0.800+0.040
4.5.4.2. Debt to Equity Ratio

Measures if Lilly is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lilly to the Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 429.4% means that company has R$4.29 debt for each R$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eli Lilly and Company:

  • The MRQ is 4.294. The company is unable to pay all its debts with equity. -1
  • The TTM is 4.343. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ4.294TTM4.343-0.049
TTM4.343YOY3.764+0.579
TTM4.3435Y6.195-1.852
5Y6.19510Y5.534+0.661
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every R$1 in earnings Lilly generates.

  • Above 15 is considered overpriced but always compare Lilly to the Drug Manufacturers - General industry mean.
  • A PE ratio of 66.90 means the investor is paying R$66.90 for every R$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eli Lilly and Company:

  • The EOD is 58.181. Based on the earnings, the company is expensive. -2
  • The MRQ is 66.896. Based on the earnings, the company is expensive. -2
  • The TTM is -413.024. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD58.181MRQ66.896-8.715
MRQ66.896TTM-413.024+479.920
TTM-413.024YOY211.857-624.881
TTM-413.0245Y223.121-636.145
5Y223.12110Y157.433+65.689
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eli Lilly and Company:

  • The EOD is 15,658.051. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 18,003.563. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 6,990.638. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD15,658.051MRQ18,003.563-2,345.512
MRQ18,003.563TTM6,990.638+11,012.925
TTM6,990.638YOY549.006+6,441.632
TTM6,990.6385Y4,309.310+2,681.328
5Y4,309.31010Y2,780.200+1,529.110
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Lilly is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 334.84 means the investor is paying R$334.84 for each R$1 in book value.

Let's take a look of the Price to Book Ratio trends of Eli Lilly and Company:

  • The EOD is 291.216. Based on the equity, the company is expensive. -2
  • The MRQ is 334.839. Based on the equity, the company is expensive. -2
  • The TTM is 264.320. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD291.216MRQ334.839-43.623
MRQ334.839TTM264.320+70.520
TTM264.320YOY702.970-438.650
TTM264.3205Y1,581.737-1,317.417
5Y1,581.73710Y1,191.778+389.959
4.6.2. Total Gains per Share

2.4. Latest News of Eli Lilly and Company

Does Eli Lilly and Company still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Eli Lilly and Company to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2024-11-06
16:33
Wegovy sales are slaying for Novo Nordisk right nowRead
2024-11-06
11:00
What can't Ozempic and other weight loss drugs cure?Read
2024-11-05
16:50
Hims & Hers will start selling a generic weight loss drugRead
2024-11-04
22:10
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk BeatRead
2024-11-01
18:21
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASHRead
2024-11-01
10:00
Eli Lilly's Zepbound sales, Pfizer wants in on weight loss drugs, AbbVie's big deal: Pharma news round upRead
2024-10-30
19:32
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worriedRead
2024-10-30
17:28
Eli Lilly Stock Plummets As Zepbound, Mounjaro Sales Miss EstimatesRead
2024-10-30
16:34
Eli Lilly Stock Tumbles After Disappointing Obesity Drug SalesRead
2024-10-25
11:30
Big Food Is Learning to Love Weight-Loss DrugsRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in BRL. All numbers in thousands.

Summary
Total Assets71,874,800
Total Liabilities58,239,300
Total Stockholder Equity13,562,000
 As reported
Total Liabilities 58,239,300
Total Stockholder Equity+ 13,562,000
Total Assets = 71,874,800

Assets

Total Assets71,874,800
Total Current Assets30,204,300
Long-term Assets41,670,500
Total Current Assets
Cash And Cash Equivalents 3,223,600
Short-term Investments 140,400
Net Receivables 11,027,900
Inventory 6,481,500
Other Current Assets 142,200
Total Current Assets  (as reported)30,204,300
Total Current Assets  (calculated)21,015,600
+/- 9,188,700
Long-term Assets
Property Plant Equipment 14,829,400
Goodwill 5,768,200
Long Term Investments 2,877,600
Intangible Assets 6,636,100
Long-term Assets Other 4,903,900
Long-term Assets  (as reported)41,670,500
Long-term Assets  (calculated)35,015,200
+/- 6,655,300

Liabilities & Shareholders' Equity

Total Current Liabilities27,121,200
Long-term Liabilities31,118,100
Total Stockholder Equity13,562,000
Total Current Liabilities
Short Long Term Debt 5,161,600
Accounts payable 2,924,800
Other Current Liabilities 4,249,200
Total Current Liabilities  (as reported)27,121,200
Total Current Liabilities  (calculated)12,335,600
+/- 14,785,600
Long-term Liabilities
Long term Debt 23,730,400
Long-term Liabilities Other 2,470,700
Long-term Liabilities  (as reported)31,118,100
Long-term Liabilities  (calculated)26,201,100
+/- 4,917,000
Total Stockholder Equity
Retained Earnings 13,178,000
Total Stockholder Equity (as reported)13,562,000
Total Stockholder Equity (calculated)13,178,000
+/- 384,000
Other
Capital Stock594,200
Common Stock Shares Outstanding 900,416
Net Debt 25,668,400
Net Invested Capital 42,454,000
Net Working Capital 3,083,100
Property Plant and Equipment Gross 26,257,200



6.2. Balance Sheets Structured

Currency in BRL. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
38,805,900
37,624,300
40,946,500
43,010,400
44,981,000
44,355,600
42,359,200
44,625,100
43,908,400
38,006,800
38,666,400
37,893,100
39,286,100
41,102,800
41,967,000
43,946,000
46,633,100
46,838,300
47,809,000
48,187,000
48,806,000
46,919,300
47,063,600
47,461,500
49,489,800
53,163,000
54,814,000
57,915,500
64,006,300
63,943,500
71,874,800
71,874,80063,943,50064,006,30057,915,50054,814,00053,163,00049,489,80047,461,50047,063,60046,919,30048,806,00048,187,00047,809,00046,838,30046,633,10043,946,00041,967,00041,102,80039,286,10037,893,10038,666,40038,006,80043,908,40044,625,10042,359,20044,355,60044,981,00043,010,40040,946,50037,624,30038,805,900
   > Total Current Assets 
15,101,400
12,976,200
15,746,500
17,428,400
19,202,100
16,261,500
18,332,700
20,685,900
20,549,600
12,597,500
13,454,500
12,661,800
13,709,600
13,994,200
14,581,900
16,239,900
17,462,100
16,604,500
17,295,500
17,808,300
18,452,400
16,964,700
17,115,200
17,639,900
18,034,500
20,811,400
21,331,600
23,007,000
25,727,000
25,188,800
30,204,300
30,204,30025,188,80025,727,00023,007,00021,331,60020,811,40018,034,50017,639,90017,115,20016,964,70018,452,40017,808,30017,295,50016,604,50017,462,10016,239,90014,581,90013,994,20013,709,60012,661,80013,454,50012,597,50020,549,60020,685,90018,332,70016,261,50019,202,10017,428,40015,746,50012,976,20015,101,400
       Cash And Cash Equivalents 
4,582,100
2,616,900
3,069,900
3,724,300
6,536,200
3,084,300
6,817,300
8,960,000
7,998,200
2,036,400
2,290,200
1,563,800
2,337,500
1,699,000
2,365,100
3,595,300
3,657,100
3,002,400
3,220,000
3,788,200
3,818,500
2,459,200
2,622,900
2,617,400
2,067,000
3,545,900
2,694,500
2,380,800
2,818,600
2,460,200
3,223,600
3,223,6002,460,2002,818,6002,380,8002,694,5003,545,9002,067,0002,617,4002,622,9002,459,2003,818,5003,788,2003,220,0003,002,4003,657,1003,595,3002,365,1001,699,0002,337,5001,563,8002,290,2002,036,4007,998,2008,960,0006,817,3003,084,3006,536,2003,724,3003,069,9002,616,9004,582,100
       Short-term Investments 
1,456,500
888,700
2,364,200
3,218,800
1,497,900
1,705,200
92,200
76,100
88,200
100,700
77,700
89,200
101,000
78,400
22,800
35,000
24,200
49,000
51,200
37,100
90,100
109,100
113,800
124,700
144,800
123,400
134,600
113,100
109,100
126,100
140,400
140,400126,100109,100113,100134,600123,400144,800124,700113,800109,10090,10037,10051,20049,00024,20035,00022,80078,400101,00089,20077,700100,70088,20076,10092,2001,705,2001,497,9003,218,8002,364,200888,7001,456,500
       Net Receivables 
4,766,300
4,613,900
4,924,800
4,991,500
5,234,600
5,265,200
5,546,100
5,616,000
6,124,400
4,200,500
4,612,500
4,441,700
5,523,100
5,106,100
4,828,900
4,886,700
5,875,300
5,592,800
6,869,700
6,992,300
8,112,500
7,763,600
7,608,400
8,086,900
8,301,800
8,901,900
9,026,600
8,167,100
9,090,500
7,885,600
11,027,900
11,027,9007,885,6009,090,5008,167,1009,026,6008,901,9008,301,8008,086,9007,608,4007,763,6008,112,5006,992,3006,869,7005,592,8005,875,3004,886,7004,828,9005,106,1005,523,1004,441,7004,612,5004,200,5006,124,4005,616,0005,546,1005,265,2005,234,6004,991,5004,924,8004,613,9004,766,300
       Inventory 
3,561,900
4,035,100
4,346,000
4,406,900
4,458,300
4,631,300
4,155,500
4,118,000
4,111,800
3,055,200
3,181,100
3,101,300
3,190,700
3,102,400
3,313,900
3,555,400
3,980,300
3,660,800
3,824,900
3,907,400
3,886,000
3,893,000
3,899,400
3,831,100
4,309,700
4,544,800
4,798,700
4,901,400
5,772,800
6,101,800
6,481,500
6,481,5006,101,8005,772,8004,901,4004,798,7004,544,8004,309,7003,831,1003,899,4003,893,0003,886,0003,907,4003,824,9003,660,8003,980,3003,555,4003,313,9003,102,4003,190,7003,101,3003,181,1003,055,2004,111,8004,118,0004,155,5004,631,3004,458,3004,406,9004,346,0004,035,1003,561,900
       Other Current Assets 
734,600
821,600
28,100
21,000
26,800
5,500
11,800
6,300
11,300
11,200
17,600
9,100
18,400
14,500
3,700
8,500
41,100
14,800
5,400
5,500
9,900
38,800
34,700
156,300
26,600
64,600
32,600
5,247,900
149,500
138,600
142,200
142,200138,600149,5005,247,90032,60064,60026,600156,30034,70038,8009,9005,5005,40014,80041,1008,5003,70014,50018,4009,10017,60011,20011,3006,30011,8005,50026,80021,00028,100821,600734,600
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
25,409,300
25,211,900
25,231,300
25,576,500
27,108,600
27,385,100
27,706,100
29,171,000
30,233,800
30,513,500
30,378,700
30,353,600
29,954,600
29,948,400
29,821,600
31,455,300
32,351,600
33,482,400
34,908,500
38,279,300
38,754,700
41,670,500
41,670,50038,754,70038,279,30034,908,50033,482,40032,351,60031,455,30029,821,60029,948,40029,954,60030,353,60030,378,70030,513,50030,233,80029,171,00027,706,10027,385,10027,108,60025,576,50025,231,30025,211,90025,409,300000000000
       Property Plant Equipment 
8,252,600
8,425,500
8,582,800
8,598,500
8,826,500
8,958,200
8,770,800
8,814,100
8,919,500
8,326,500
8,393,000
8,337,200
8,405,000
7,897,900
7,981,100
8,281,100
8,681,900
8,630,100
8,855,500
8,920,400
8,985,100
9,102,700
9,128,200
9,311,300
10,144,000
10,546,200
11,277,400
11,863,200
12,913,600
13,624,000
14,829,400
14,829,40013,624,00012,913,60011,863,20011,277,40010,546,20010,144,0009,311,3009,128,2009,102,7008,985,1008,920,4008,855,5008,630,1008,681,9008,281,1007,981,1007,897,9008,405,0008,337,2008,393,0008,326,5008,919,5008,814,1008,770,8008,958,2008,826,5008,598,5008,582,8008,425,5008,252,600
       Goodwill 
3,972,700
4,188,000
4,290,800
4,365,600
4,370,100
4,412,400
4,333,100
4,358,400
4,347,500
3,855,900
3,820,100
3,772,500
3,679,400
3,779,100
3,723,200
3,726,400
3,766,500
3,877,400
3,884,200
3,884,100
3,892,000
3,892,000
3,891,800
3,891,600
4,073,000
4,073,100
4,078,900
4,085,200
4,939,700
4,939,600
5,768,200
5,768,2004,939,6004,939,7004,085,2004,078,9004,073,1004,073,0003,891,6003,891,8003,892,0003,892,0003,884,1003,884,2003,877,4003,766,5003,726,4003,723,2003,779,1003,679,4003,772,5003,820,1003,855,9004,347,5004,358,4004,333,1004,412,4004,370,1004,365,6004,290,8004,188,0003,972,700
       Long Term Investments 
5,207,500
5,297,700
5,767,900
6,191,700
5,713,900
5,379,200
2,080,800
2,012,700
2,033,400
2,111,400
1,852,700
1,825,300
1,962,400
2,148,700
2,406,400
2,476,200
2,966,800
3,232,400
3,474,900
3,350,500
3,212,600
2,727,300
2,587,200
2,574,600
2,901,800
2,750,400
2,745,100
2,691,700
3,052,200
3,086,900
2,877,600
2,877,6003,086,9003,052,2002,691,7002,745,1002,750,4002,901,8002,574,6002,587,2002,727,3003,212,6003,350,5003,474,9003,232,4002,966,8002,476,2002,406,4002,148,7001,962,4001,825,3001,852,7002,111,4002,033,4002,012,7002,080,8005,379,2005,713,9006,191,7005,767,9005,297,7005,207,500
       Intangible Assets 
4,357,900
4,716,700
4,542,600
4,271,600
4,029,200
3,920,000
3,772,100
3,619,400
3,521,000
6,641,500
6,586,600
6,689,300
6,618,000
7,766,700
7,712,500
7,588,600
7,450,000
8,087,800
7,985,400
7,887,700
7,691,900
7,482,400
7,497,700
7,124,100
7,206,600
7,087,100
6,903,500
6,781,700
6,906,600
6,762,200
6,636,100
6,636,1006,762,2006,906,6006,781,7006,903,5007,087,1007,206,6007,124,1007,497,7007,482,4007,691,9007,887,7007,985,4008,087,8007,450,0007,588,6007,712,5007,766,7006,618,0006,689,3006,586,6006,641,5003,521,0003,619,4003,772,1003,920,0004,029,2004,271,6004,542,6004,716,7004,357,900
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
1,963,000
2,052,100
2,194,200
2,339,100
3,044,600
3,080,100
3,078,500
3,475,400
3,756,200
3,638,600
3,710,400
4,082,700
4,285,300
4,471,600
4,535,700
4,337,000
4,488,100
4,671,600
4,911,900
4,989,900
4,708,100
4,903,900
4,903,9004,708,1004,989,9004,911,9004,671,6004,488,1004,337,0004,535,7004,471,6004,285,3004,082,7003,710,4003,638,6003,756,2003,475,4003,078,5003,080,1003,044,6002,339,1002,194,2002,052,1001,963,000000000000
> Total Liabilities 
24,725,400
23,520,600
26,776,800
28,049,800
33,313,100
29,767,800
30,738,400
30,474,200
32,999,300
35,441,800
35,809,100
34,430,800
36,587,000
38,024,000
37,874,100
39,119,100
40,991,500
39,939,600
41,145,500
40,232,900
39,651,200
37,457,300
38,404,400
37,295,600
38,840,000
41,972,600
43,750,200
46,695,100
53,142,600
51,046,100
58,239,300
58,239,30051,046,10053,142,60046,695,10043,750,20041,972,60038,840,00037,295,60038,404,40037,457,30039,651,20040,232,90041,145,50039,939,60040,991,50039,119,10037,874,10038,024,00036,587,00034,430,80035,809,10035,441,80032,999,30030,474,20030,738,40029,767,80033,313,10028,049,80026,776,80023,520,60024,725,400
   > Total Current Liabilities 
10,986,600
10,448,000
11,294,500
12,666,500
14,535,900
11,547,000
13,055,200
10,826,700
11,888,100
11,236,100
11,855,400
10,828,600
11,775,200
12,610,200
11,988,500
11,976,900
12,481,600
11,714,200
15,093,200
13,682,000
15,052,700
13,386,000
15,620,600
15,652,800
17,138,200
16,010,000
18,915,000
21,998,200
27,293,200
18,598,100
27,121,200
27,121,20018,598,10027,293,20021,998,20018,915,00016,010,00017,138,20015,652,80015,620,60013,386,00015,052,70013,682,00015,093,20011,714,20012,481,60011,976,90011,988,50012,610,20011,775,20010,828,60011,855,40011,236,10011,888,10010,826,70013,055,20011,547,00014,535,90012,666,50011,294,50010,448,00010,986,600
       Short-term Debt 
1,937,400
2,609,300
12,341,000
13,530,800
1,038,700
853,200
625,800
621,800
659,300
2,354,900
2,068,600
1,563,100
1,499,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000001,499,3001,563,1002,068,6002,354,900659,300621,800625,800853,2001,038,70013,530,80012,341,0002,609,3001,937,400
       Short Long Term Debt 
1,937,400
2,609,300
12,341,000
13,530,800
1,038,700
853,200
625,800
621,800
659,300
2,354,900
2,068,600
1,563,100
1,499,300
3,248,000
1,263,800
587,500
8,700
4,900
1,778,500
1,563,000
1,538,300
1,355,900
2,121,800
1,744,600
1,501,100
3,100
661,600
2,244,700
6,904,500
1,651,500
5,161,600
5,161,6001,651,5006,904,5002,244,700661,6003,1001,501,1001,744,6002,121,8001,355,9001,538,3001,563,0001,778,5004,9008,700587,5001,263,8003,248,0001,499,3001,563,1002,068,6002,354,900659,300621,800625,800853,2001,038,70013,530,80012,341,0002,609,3001,937,400
       Accounts payable 
2,913,400
1,908,600
1,257,200
1,200,100
1,410,700
1,267,400
1,316,900
1,281,200
1,412,300
1,168,100
1,198,900
1,114,900
1,405,300
1,207,700
1,247,200
1,430,100
1,606,700
1,639,600
1,597,800
1,566,800
1,670,600
1,433,300
1,659,300
1,683,200
1,930,600
2,015,900
2,474,200
2,435,100
2,598,800
2,473,700
2,924,800
2,924,8002,473,7002,598,8002,435,1002,474,2002,015,9001,930,6001,683,2001,659,3001,433,3001,670,6001,566,8001,597,8001,639,6001,606,7001,430,1001,247,2001,207,7001,405,3001,114,9001,198,9001,168,1001,412,3001,281,2001,316,9001,267,4001,410,7001,200,1001,257,2001,908,6002,913,400
       Other Current Liabilities 
6,135,800
5,930,100
2,880,200
2,730,700
3,850,100
2,996,000
3,208,900
2,536,100
3,164,900
2,254,300
2,189,200
1,988,400
2,805,800
2,883,000
3,514,600
3,388,200
3,697,200
3,552,900
3,878,400
2,513,000
3,814,100
3,135,000
3,012,300
2,672,500
3,591,300
3,711,900
4,512,900
2,585,400
3,281,300
4,199,100
4,249,200
4,249,2004,199,1003,281,3002,585,4004,512,9003,711,9003,591,3002,672,5003,012,3003,135,0003,814,1002,513,0003,878,4003,552,9003,697,2003,388,2003,514,6002,883,0002,805,8001,988,4002,189,2002,254,3003,164,9002,536,1003,208,9002,996,0003,850,1002,730,7002,880,2005,930,1006,135,800
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
24,205,700
23,953,700
23,602,200
24,811,800
25,295,400
25,706,500
26,973,100
28,326,300
28,024,800
26,052,300
26,550,900
24,598,500
24,071,300
22,783,800
21,642,800
21,576,200
25,858,100
24,749,700
24,609,900
25,849,400
32,448,000
31,118,100
31,118,10032,448,00025,849,40024,609,90024,749,70025,858,10021,576,20021,642,80022,783,80024,071,30024,598,50026,550,90026,052,30028,024,80028,326,30026,973,10025,706,50025,295,40024,811,80023,602,20023,953,70024,205,700000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,586,600
16,199,600
14,736,600
15,522,400
15,346,400
0
0
14,143,800
14,737,500
18,880,500
18,158,400
17,923,600
0
0
0
00017,923,60018,158,40018,880,50014,737,50014,143,8000015,346,40015,522,40014,736,60016,199,60016,586,6000000000000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
508,200
503,300
485,200
486,700
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000486,700485,200503,300508,200000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
1,169,800
1,142,800
1,100,400
1,014,300
1,873,000
1,826,800
1,702,600
1,707,500
1,737,300
1,801,900
1,748,700
1,644,300
1,713,900
1,783,100
1,852,900
1,736,700
1,822,500
1,951,800
1,906,100
2,240,600
2,270,800
2,470,700
2,470,7002,270,8002,240,6001,906,1001,951,8001,822,5001,736,7001,852,9001,783,1001,713,9001,644,3001,748,7001,801,9001,737,3001,707,5001,702,6001,826,8001,873,0001,014,3001,100,4001,142,8001,169,800000000000
> Total Stockholder Equity
14,007,700
14,031,000
14,100,800
14,890,300
11,592,200
14,527,000
11,555,200
13,076,600
9,828,700
2,480,300
2,780,500
3,382,500
2,606,900
3,078,800
4,092,900
4,826,900
5,641,600
6,898,700
6,444,400
7,757,000
8,979,200
9,330,800
8,544,700
10,070,100
10,649,800
11,190,400
11,063,800
11,220,400
10,771,900
12,812,200
13,562,000
13,562,00012,812,20010,771,90011,220,40011,063,80011,190,40010,649,80010,070,1008,544,7009,330,8008,979,2007,757,0006,444,4006,898,7005,641,6004,826,9004,092,9003,078,8002,606,9003,382,5002,780,5002,480,3009,828,70013,076,60011,555,20014,527,00011,592,20014,890,30014,100,80014,031,00014,007,700
   Retained Earnings 
16,046,300
15,876,700
15,590,100
16,145,500
13,894,100
16,608,200
14,247,300
14,408,700
11,395,900
4,879,400
4,318,100
4,981,900
4,920,400
5,879,400
6,617,200
7,154,000
7,830,200
9,181,300
8,530,100
9,639,400
8,958,500
9,369,400
8,556,000
10,006,500
10,042,600
10,639,300
10,368,500
10,309,900
10,312,300
12,553,900
13,178,000
13,178,00012,553,90010,312,30010,309,90010,368,50010,639,30010,042,60010,006,5008,556,0009,369,4008,958,5009,639,4008,530,1009,181,3007,830,2007,154,0006,617,2005,879,4004,920,4004,981,9004,318,1004,879,40011,395,90014,408,70014,247,30016,608,20013,894,10016,145,50015,590,10015,876,70016,046,300
   Accumulated Other Comprehensive Income 0000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
6,556,100
6,629,400
6,698,800
6,778,500
6,579,200
6,669,200
6,758,000
6,833,400
0
0
6,829,000
6,921,400
6,793,100
6,948,600
7,160,000
0
0
0
0007,160,0006,948,6006,793,1006,921,4006,829,000006,833,4006,758,0006,669,2006,579,2006,778,5006,698,8006,629,4006,556,1000000000000000
   Treasury Stock0000000000-52,700-52,700-52,700-52,700-55,700-55,700-55,700-55,7000000000000000



6.3. Balance Sheets

Currency in BRL. All numbers in thousands.




6.4. Cash Flows

Currency in BRL. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in BRL. All numbers in thousands.

Gross Profit (+$)
totalRevenue34,124,100
Cost of Revenue-7,082,200
Gross Profit27,041,90027,041,900
 
Operating Income (+$)
Gross Profit27,041,900
Operating Expense-23,336,800
Operating Income10,787,3003,705,100
 
Operating Expense (+$)
Research Development9,313,400
Selling General Administrative6,941,200
Selling And Marketing Expenses-
Operating Expense23,336,80016,254,600
 
Net Interest Income (+$)
Interest Income173,600
Interest Expense-485,900
Other Finance Cost-0
Net Interest Income-312,300
 
Pretax Income (+$)
Operating Income10,787,300
Net Interest Income-312,300
Other Non-Operating Income Expenses-
Income Before Tax (EBT)6,554,60014,707,700
EBIT - interestExpense = -485,900
5,240,400
5,726,300
Interest Expense485,900
Earnings Before Interest and Taxes (EBIT)-7,040,500
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax6,554,600
Tax Provision-1,314,200
Net Income From Continuing Ops5,240,4005,240,400
Net Income5,240,400
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-3,920,400312,300
 

Technical Analysis of Lilly
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lilly. The general trend of Lilly is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lilly's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Eli Lilly and Company.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 155.85 < 174.50 < 176.32.

The bearish price targets are: 143.07 > 138.06 > 135.19.

Tweet this
Eli Lilly and Company Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eli Lilly and Company. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Eli Lilly and Company Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eli Lilly and Company. The current macd is -3.89005605.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lilly price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Lilly. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Lilly price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Eli Lilly and Company Daily Moving Average Convergence/Divergence (MACD) ChartEli Lilly and Company Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Eli Lilly and Company. The current adx is 25.43.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Lilly shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Eli Lilly and Company Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eli Lilly and Company. The current sar is 168.80.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Eli Lilly and Company Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eli Lilly and Company. The current rsi is 26.89. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Eli Lilly and Company Daily Relative Strength Index (RSI) ChartEli Lilly and Company Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eli Lilly and Company. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Lilly price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Eli Lilly and Company Daily Stochastic Oscillator ChartEli Lilly and Company Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eli Lilly and Company. The current cci is -177.69859266.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Eli Lilly and Company Daily Commodity Channel Index (CCI) ChartEli Lilly and Company Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eli Lilly and Company. The current cmo is -61.00769782.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Eli Lilly and Company Daily Chande Momentum Oscillator (CMO) ChartEli Lilly and Company Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Eli Lilly and Company. The current willr is -95.12114172.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Eli Lilly and Company Daily Williams %R ChartEli Lilly and Company Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Eli Lilly and Company.

Eli Lilly and Company Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eli Lilly and Company. The current atr is 5.78071924.

Eli Lilly and Company Daily Average True Range (ATR) ChartEli Lilly and Company Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eli Lilly and Company. The current obv is 256,190.

Eli Lilly and Company Daily On-Balance Volume (OBV) ChartEli Lilly and Company Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eli Lilly and Company. The current mfi is 12.08.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Eli Lilly and Company Daily Money Flow Index (MFI) ChartEli Lilly and Company Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Eli Lilly and Company.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-06-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-01MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Eli Lilly and Company Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Eli Lilly and Company based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5026.894
Ma 20Greater thanMa 50167.658
Ma 50Greater thanMa 100168.322
Ma 100Greater thanMa 200166.605
OpenGreater thanClose157.000
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Lilly with someone you think should read this too:
  • Are you bullish or bearish on Lilly? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lilly? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Eli Lilly and Company

I send you an email if I find something interesting about Eli Lilly and Company.


Comments

How you think about this?

Leave a comment

Stay informed about Eli Lilly and Company.

Receive notifications about Eli Lilly and Company in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.